Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFIRINOX vs Modified FOLFOX in Small Bowel Adenocarcinoma
NCT06278545Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Percentage of patients alive without progression at 8 months. Started Feb 2024; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT06278545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278545.